<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111496</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02398-49</org_study_id>
    <nct_id>NCT05111496</nct_id>
  </id_info>
  <brief_title>Evaluation of the Radiological Dose Delivered to Risky Interventional Cardiology Patients (Optidose)</brief_title>
  <acronym>Optidose</acronym>
  <official_title>Evaluation of the Radiological Dose Delivered to Risky Interventional Cardiology Patients (Optidose)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsay Générale de Santé</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Clinical Trial Experts Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramsay Générale de Santé</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is therefore to study the actual doses of X-rays delivered to the&#xD;
      patient's skin during recanalization of a coronary artery in a context of Chronic Total&#xD;
      Occlusion&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">November 24, 2021</completion_date>
  <primary_completion_date type="Actual">October 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dose measured to the patient's skin at the entrance to the X-ray beam</measure>
    <time_frame>1 month</time_frame>
    <description>Dose expressed in Gy (Peak skin dose).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">85</enrollment>
  <condition>X-rays; Effects</condition>
  <condition>Chronic Total Occlusion</condition>
  <arm_group>
    <arm_group_label>Patient requiring intervention (complex coronary dilation or coronary recanalization)</arm_group_label>
    <description>Patient requiring intervention with a predicted risk of exceeding the radiological threshold (Air Kerma&gt; 3Gy): complex coronary dilation, coronary recanalization</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gafchromic film</intervention_name>
    <description>Before the X-ray radiation, a Gafchromic film will be placed on the patient's back at the start of the operation</description>
    <arm_group_label>Patient requiring intervention (complex coronary dilation or coronary recanalization)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient over 18 years-old, requiring intervention with a predicted risk of exceeding the&#xD;
        radiological threshold (Air Kerma&gt; 3Gy): complex coronary dilation, coronary recanalization&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years-old&#xD;
&#xD;
          -  Patient requiring intervention with a predicted risk of exceeding the radiological&#xD;
             threshold (Air Kerma&gt; 3Gy): complex coronary dilation, coronary recanalization&#xD;
&#xD;
          -  Patient benefiting from a social protection insurance&#xD;
&#xD;
          -  Patient having been informed and not objecting to this research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal to participate in the study&#xD;
&#xD;
          -  Patient with known radiosensitivity factors (eg: Lupus)&#xD;
&#xD;
          -  Patient having had radiotherapy treatment of the thoracic region.&#xD;
&#xD;
          -  Patient whose sum of radiation doses to the skin&gt; 0.5 Gy in the thoracic region in the&#xD;
             3 months preceding inclusion.&#xD;
&#xD;
          -  Patient participating in another clinical study&#xD;
&#xD;
          -  Protected patient: adult under guardianship, curatorship or other legal protection,&#xD;
             deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient hospitalized without consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-François Oudet</last_name>
    <phone>0683346567</phone>
    <email>jf.oudet@ecten.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Hélène Barba</last_name>
    <email>mh.barba@ecten.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital privé La Louvière</name>
      <address>
        <city>Lille</city>
        <state>Haut De France</state>
        <zip>59800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Barba</last_name>
      <phone>+330664888704</phone>
      <phone_ext>+330664888704</phone_ext>
      <email>mh.barba@ecten.eu</email>
    </contact>
    <contact_backup>
      <last_name>Jean Francois OUDET</last_name>
      <phone>+33683346567</phone>
      <phone_ext>+33683346567</phone_ext>
      <email>jf.oudet@ecten.eu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

